- Policy
- Reblozyl was approved after 1 yr of designation of rare drug
- by Lee, Hye-Kyung May 11, 2022 05:55am
- Reblozyl 25mg, a treatment for patients with beta-Mediterranean anemia, was officially approved for items a year after designation as a rare drug. The MFDS approved Reblozyl applied by BSM Pharmaceutical Korea. Reblozyl is equipped with▲ the treatment of adult beta-Mediterranean anemia patients who need red blood cell transfusion as an
- Policy
- President Yoon said he was grateful to the people
- by Lee, Jeong-Hwan May 11, 2022 05:55am
- President Yoon Seok-yeol said on the 10th, "I am deeply grateful to the medical staff for their respect and dedication to the people who have endured great pain in the process of overcoming the COVID-19 pandemic over the past two years." At the inauguration ceremony of the 20th president held in front of the main building of the National Asse
- Policy
- Only 40% of asthma pts undergo Pulmonary function testing
- by Lee, Tak-Sun May 6, 2022 05:46am
- Although it is recommended to take pulmonary function test at least once a year to manage diseases in asthma patients, only less than half of all patients are tested. The HIRA announced on the 3rd that it will analyze and disclose the results of the 2020 (8th) asthma adequacy evaluation to mark World Asthma Day. As a result of the evaluation,
- Policy
- New cost of Tecentriq is 2,271,109 won
- by Kim, Jung-Ju May 2, 2022 06:02am
- Tecentriq, an immuno-cancer drug from Roche Korea, will be expanded from next month due to a combination treatment with Avastin. The new insurance drug price is 2,271,109 won per 20mL for Tecentriq, 218,782 won per 100mg for Avastin, and 712,098 won for Avastin 400mg. The MOHW announced that the "Amendment to the Pharmaceutical Benefit
- Policy
- Combi of HBP+ Hyperlipidemia will be released again
- by Lee, Tak-Sun Apr 29, 2022 05:41am
- As Chong Kun Dang, Yuhan Corp., and GC Pharma, one of the top three traditional pharmaceutical companies in sales, are set to launch a combination of high blood pressure + hyperlipidemia, the market is expected to lead the prescription trend in the future. Currently, the market is led by improved complexes developed by Boryung, Hanmi Pharmace
- Policy
- Reviewing the removal of outdoor masks
- by Lee, Jeong-Hwan Apr 28, 2022 06:06am
- The presidential transition committee announced its position to examine the COVID-19 situation in late May, a month after the launch of the new government, and then decide to release the outdoor mask. The new government plans to promote quarantine policies based on scientific evidence and prepare governance to respond to infectious disease
- Policy
- The transition team operates biohealth regulatory sandboxes
- by Kang, Shin-Kook Apr 27, 2022 06:03am
- The presidential transition committee established the Pharmaceutical Bio Innovation Committee, which was the pledge of Yoon Seok-yeol, and presented deregulation through biohealth regulatory sandboxes as a policy task. Baek Kyung-ran, a member of the transition team's social welfare division, said on the 25th that he will recognize the biohea
- Policy
- Betamethasone's permission change is expected
- by Lee, Hye-Kyung Apr 27, 2022 06:03am
- As a result of reviewing safety information on drugs containing the skin disease treatment Betamethasone, precautions for use such as Pheochromocytoma are expected to be added. The MFDS' Pharmaceutical Safety Evaluation Division prepared a change (draft) of permission based on the results of the European Medicines Agency's review of safety
- Policy
- Phase III for development of Alecensa & Keytruda
- by Lee, Hye-Kyung Apr 26, 2022 06:11am
- Roche Korea and MSD Korea are accelerating clinical trials to develop combination therapy for non-small cell lung cancer treatments. On the 22nd, the MFDS approved phase 3 clinical trials of MSD's Keytruda and Keytruda SC and Roche's Alecensa. All of these pharmaceutical companies begin clinical trials to confirm the safety and effectiv
- Policy
- Exclude drugs that have increased due to COVID-19 from PVA
- by Lee, Tak-Sun Apr 25, 2022 06:08am
- It is reported that the pharmaceutical industry plans to officially propose to the government to exclude respiratory treatments that have increased their use due to the increase in COVID-19 patients from PVA. It is asked to reflect that the explosive increase in the use of the drug is inevitable due to the increase in the number of patients w
